|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
3150 Almaden Expy, Suite 250, San Jose, California 95118, US
|
|
Anixa Biosciences (NASDAQ:ANIX) is a clinical stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer--specifically triple negative breast cancer (TNBC), the most lethal form of the disease--as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.
|
Anixa Biosciences, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Anixa Biosciences, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Anixa Biosciences, Inc. customer service number in your country click here to find.
Amit Kumar is the CEO of Anixa Biosciences, Inc.. To contact Amit Kumar email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.